文献速递银屑病与炎症性皮肤病

银屑病外用治疗可及性与体表面积对外用治疗使用的影响:问卷调查研究

Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-04-19

该研究为观察性横断面调查,向国际银屑病理事会(IPC)皮肤科医生发放问卷,评估26个国家外用治疗可及性及体表面积(BSA)分类如何影响外用治疗决策。结果显示焦油、外用维A酸、地蒽酚和浴疗的可获得性存在差异;绝大多数受访者在BSA<3%和BSA 3%–10%时使用外用治疗作为一线单药治疗,但BSA>10%时处方外用治疗的人数明显减少,且常报告外用药物与系统药物联合治疗。

要点

  • BSA<3%时100%受访者、BSA 3%–10%时88.4%受访者将外用治疗作为一线单药治疗。
  • BSA>10%时处方外用治疗的受访者人数明显减少,常改为外用联合系统治疗。
  • 焦油、外用维A酸、地蒽酚和浴疗的可获得性在26个国家间存在差异。

核心结论

  • 银屑病外用治疗的可及性存在跨地区差异,疾病严重度(BSA)影响外用治疗的使用方式。
  • 该医生调查为全球层面改进治疗策略提供了新证据。

研究设计与样本

  • 观察性横断面研究,向国际银屑病理事会(IPC)皮肤科医生发放问卷。
  • 调查评估26个国家的外用治疗可及性及BSA分类对临床决策的影响。

主要发现

  • 焦油、外用维A酸、地蒽酚和浴疗的可获得性存在差异。
  • BSA<3%时100%受访者、BSA 3%–10%时88.4%受访者将外用治疗作为一线单药治疗。
  • BSA>10%时处方外用治疗的受访者人数明显减少,且常报告外用药物与系统药物联合治疗。

关键数值与推荐

  • BSA<3%:100%受访者使用外用治疗作为一线单药治疗。
  • BSA 3%–10%:88.4%受访者使用外用治疗作为一线单药治疗。
  • BSA>10%:处方外用治疗的受访者人数明显减少,常采用外用联合系统治疗。

临床怎么用

  • 提示临床医生在BSA<3%及3%–10%的轻中度银屑病中可优先考虑外用治疗。
  • BSA>10%时应考虑外用联合系统治疗,而非单纯外用治疗。
  • 需关注不同国家间外用药物可获得性差异对治疗选择的影响。

局限性

  • 原文未报告调查样本量、应答率及具体统计检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topical treatment of mild to moderate psoriasis is first-line treatment and exhibits varying degrees of success across patient groups. Key factors influencing treatment success are physician topical treatment choice (high efficacy, low adverse events) and strict patient adherence. Currently, no formalized, international consensus guidelines exist to direct optimal topical treatment, although many countries have national guidelines. OBJECTIVE: To describe and analyse cross-regional variations in the use and access of psoriasis topical therapies. METHODS: The study was conducted as an observational cross-sectional study. A survey was distributed to dermatologists from the International Psoriasis Council (IPC) to assess topical therapy accessibility in 26 countries and to understand how body surface area (BSA) categories guide clinical decisions on topical use. RESULTS: Variation in the availability of tars, topical retinoids, dithranol and balneotherapy was reported. The vast majority of respondents (100% and 88.4%) used topical therapy as first-line monotherapy in situations with BSA < 3% and BSA between 3% and 10%, respectively. However, with disease severity increasing to BSA > 10%, the number of respondents who prescribe topical therapy decreased considerably. In addition, combination therapy of a topical drug and a systemic drug was frequently reported when BSA measured >10%. CONCLUSION: This physician survey provides new evidence on topical access and the influence of disease severity on topical usage in an effort to improve treatment strategies on a global level.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Iversen L, Lange MM, Bissonette R, et al. Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. J Eur Acad Dermatol Venereol. 2017. PMID: 28370534. doi:10.1111/jdv.14250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。